ArticleClinical & translational immunology2022

YTHDF2 promotes temozolomide resistance in glioblastoma by activation of the Akt and NF-κB signalling pathways via inhibiting EPHB3 and TNFAIP3.

Yu Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.